Adapting to change and operating within an uncertain regulatory environment is a constant reality of the legalized cannabis and natural medicine industries.
The fast growth, maze of regulations, and financial and operational constraints, create challenges for operators, growers, and investors alike. Our experienced team helps businesses navigate this dynamic marketplace.
New products using hemp, marijuana, CBD, and other cannabinoids hit the market every day. Research into psychedelics that hold promise for new frontiers of healing and pain management is underway. Businesses are subject to a host of unique legal pitfalls with licensing and compliance, including thorny tax issues (Section 280E), and the patchwork of state and local laws, all while operating in a federally illegal landscape.
Several states have, or are in the process of, passing laws and regulations that permit research or the lawful distribution of natural medicines, including psilocybin ("magic mushrooms") and other plant-derived substances. Our team is poised to help companies proactively set up a tax-optimal business structure, pursue financing, licensing, and comply with evolving state and local regulatory changes.
Cannabis may soon enter uncharted territory as a Schedule III controlled substance, which will open up a host of opportunities and remove the harsh tax burden of Section 280E (absent Congressional action to maintain it). If and when rescheduling occurs, our team will help businesses cut through the ensuing red tape.
The still-emerging cannabis and natural medicine industries face novel legal complexity. Leveraging experience from the first state cannabis legalization efforts, our team guides clients to ensure operational compliance. We also build productive relationships with state, local, and federal authorities while zealously advocating to ensure your rights are protected and your business interests advance.